| Age |
median (IQR) |
38 (33-46) |
| >50 years, n(%) |
30 (13) |
| ≤50 years, n(%) |
201 (87) |
| Female |
160 (69.26) |
| HIV type 1, n(%) |
221 (95.67) |
| Baseline CD4 cells count |
median (IQR) |
148 (78-220) |
| <200/mm3, n(%) |
158 (68.4) |
| ≥200/mm3, n(%) |
73 (31.6) |
| Karnofsky score, median (IQR) |
90 (90-90) |
| CDC Clinic stage |
stage A or B, n(%) |
172 (74.46) |
| stage C, n(%) |
59 (25.54) |
| Presence of opportunistic infections, n(%) |
158 (68.4) |
| |
NNRTI-based regimens |
NVP-based regimen, n(%) |
192 (88.9) |
| EFV-based regimen, n(%) |
24 (11.1) |
| PI-based regimen, n(%) |
9 (3.9) |
| 3 NRTIs regimen, n(%) |
6 (2.6) |
| Cotrimoxazole prophylaxis, n(%) |
208 (90) |
| Socio-economic condition |
Low condition, n(%) |
185 (80.10%) |
| Medium or high condition, n(%) |
46 (19.9%) |
| Housing condition |
Standing, n(%) |
110 (47.7%) |
| Modest, n(%) |
115 (49.8%) |
| Precarious, n(%) |
6 (2.6%) |
| Education |
Illiteracy or primary school level, n(%) |
137 (85.7%) |
| Secondary or high school level, n(%) |
94 (40.7%) |
IQR: interquartile range |
